FindTrial
Sign In

Exploring Freeflex Emulgel for Easing Joint Pain in Children with Bleeding Disorder

A Pilot Study Assessing the Efficacy and Safety of FreeFlex Emulgel in Pediatric Patients with Hemophilic Arthropathy - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082602
Enrollment
30
Registered
2025-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M362- Hemophilic arthropathy

Interventions

Intervention1: FreeFlex Emulgel: Once/ twice daily for 4 weeks

Sponsors

Dr Pamela Narayan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pediatric patients diagnosed with haemophilia. 2. Documented history of knee joint pain and swelling due to haemophilia-induced arthropathy, confirmed through clinical assessment and imaging if needed.

Exclusion criteria

Exclusion criteria: 1. Patients with known allergies to glucosamine, chondroitin, or other components of FreeFlex Emulgel. 2. Patients currently using other topical treatments for joint pain. 3. Presence of any severe systemic illness or infection that could interfere with the study. 4. Any children with hemophilia (cwh) with an acute knee joint bleed. 5. Children with hemophilia (cwh) who are on secondary prophylaxis.

Design outcomes

Primary

MeasureTime frame
To evaluate efficacy of FreeFlex EmulgelTimepoint: 4 weeks—

Secondary

MeasureTime frame
To assess safety and tolerability of FreeFlex EmulgelTimepoint: 4 weeks;To assess quality of life pre and post-treatment with FreeFlex EmulgelTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactDr Pamela Narayan

Lakshmi Hospital & Research Centre

pamelanarayan@yahoo.co.in9948041563

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026